WANETAM 2

Background

Building on the achievements registered and lessons learnt in WANETAM 1, WANETAM 2 was implemented from 2017 to 2020. This phase included 16 institutions from nine West African Countries and four institutions from Europe.

Objectives

WANETAM 2 was aimed at attaining sustainable expertise for conducting clinical trials, research and implementing control of poverty related diseases in West Africa

Institutions

Burkina Faso

  • Centre Muraz

Guinea Bissau

  • Instituto Nacional de Saúde Pública

France

  • Institut de Recherche pour le Développement

Gambia

  • MRC Unit The Gambia at LSHTM
  • National Public Health Laboratories

Germany

  • Forschungszentrum Borstel Leibniz-Zentrum fur Medizin und Biowissenschaften

Ghana

  • Korle-Bu Teaching Hospital
  • Noguchi Memorial Institute for Medical Research

Mali

  • Malaria Research and Training Center

Nigeria

  • Nigerian Institute of Medical Research
  • Institute of Human Virology
  • University of Ibadan
  • Jos University Teaching Hospital

Portugal

  • Universidade Nova de Lisboa

Senegal

  • Réseau Africain de Recherche sur le SIDA
  • Institut Pasteur de Dakar
  • Université Cheikh Anta Diop

Sierra Leone

  • College of Medicine and Allied Health Sciences

Togo

  • Laboratoire National de Référence

United Kingdom

  • London School of Hygiene and Tropical Medicine

Achievements

At the end of WANETAM 2, the following are some of the achievements that were registered: Strengthened targeted trainings on strategic skills including the training of 12 Project Managers coming from 12 partner institutions to support clinical trials and other clinical research within the region.

  • Developed the shared use of platforms and resources.
  • Supported 2 laboratories to obtain ISO 15189 accreditation.
  • 10 auditors across the network Certified CQI-IRCA ISO 9001:2015 Lead Auditors.
  • Developed a training and mentorship plan to support career and leadership development of talented individuals.
  • One ICH-GCP-compliant clinical trial on Control Human Malaria Infection (CHMI) Trial was implemented in The Gambia and resulted in a publication in a peer-reviewed journal. The study also provided the opportunity to train a young scientist from Burkina Faso on clinical trials.
  • The TB work package demonstrated active collaboration and coordination by publishing a policy paper on the impact of Covid-19 on TB patients and TB control program.
  • The childhood TB work stream successfully formed a sub-network, the West African Paediatric TB Network (WApTBNet), comprising researchers, clinicians, laboratory scientists, and national TB programme officers with focused interest in childhood TB. Building upon the multi-disciplinary platform of the WANETAM TB Work Package, the WApTBNet designed and implemented a multi-country clinical research study that is pragmatically investigating the diagnostic accuracy of “Xpert Ultra” assay, and the epidemiology of drug-resistant TB, in prospectively recruited children with presumptive TB from five WANETAM institutions across four countries.